US 12,460,267 B2
Compositions and methods for detection of Mycoplasma genitalium
Jody Harris, Lafayette, CA (US); and Kalyani Mangipudi, Pleasanton, CA (US)
Assigned to Roche Molecular Systems, Inc., Pleasanton, CA (US)
Filed by Roche Molecular Systems, Inc., Pleasanton, CA (US)
Filed on Jan. 12, 2023, as Appl. No. 18/153,927.
Application 18/153,927 is a division of application No. 16/800,938, filed on Feb. 25, 2020, granted, now 11,591,659.
Application 16/800,938 is a division of application No. 15/601,545, filed on May 22, 2017, granted, now 10,612,101, issued on Apr. 7, 2020.
Claims priority of provisional application 62/342,519, filed on May 27, 2016.
Prior Publication US 2023/0143647 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12Q 1/68 (2018.01); C12Q 1/686 (2018.01); C12Q 1/689 (2018.01)
CPC C12Q 1/689 (2013.01) [C12Q 1/686 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 5 Claims
 
1. A kit for detecting a nucleic acid of Mycoplasma genitalium (MG) comprising:
a forward primer consisting of a first oligonucleotide sequence selected from the group consisting of SEQ ID NOs: 48, 49, 53, 54, 55 and 56;
a reverse primer consisting of a second oligonucleotide sequence selected from the group consisting of SEQ ID NOs: 58, 62, 63, 64, 65 and 66; and
a fluorescent detectably labeled probe consisting of a third oligonucleotide sequence selected from the group consisting of SEQ ID NOs: 68, 71-88 and 89, the detectably labeled probe configured to hybridize to an amplicon generated by the first primer and the second primer.